News > Aromatase inhibitors outperform tamoxifen in young women with ER+ breast cancer and OFS

Aromatase inhibitors outperform tamoxifen in young women with ER+ breast cancer and OFS

Latest findings reveal new, better recurrence prevention option

general_content


Premenopausal women with ER+ breast cancer have new options for endocrine (hormone) therapy. Studies show that aromatase inhibitors are more effective than tamoxifen in preventing cancer from coming back if ovarian function is suppressed. This research was presented in two sessions on December 8 at the San Antonio Breast Cancer Symposium (SABCS).

Background



Tamoxifen and aromatase inhibitors are two different kinds of endocrine therapy. They are typically given to women with ER+ breast cancer after treatment has ended to prevent recurrence.



Tamoxifen has long been the mainstay in women with ER+ breast cancer. A 2011 study in Lancet found that it reduced 15-year breast cancer mortality by one-third.



Aromatase inhibitors (AIs) are even more effective than tamoxifen in postmenopausal women, as reported in a 2015 study in Lancet. Premenopausal women typically do not benefit from AIs.



Ovarian function suppression (OFS) prevents the body from making estrogen. OFS can be achieved through surgery or medicines.



Dana-Farber Cancer Institute’s SOFT trial found that tamoxifen plus OFS works better than tamoxifen alone in preventing recurrence. SOFT, and a second trial (TEXT), compared tamoxifen with OFS to AIs with OFS in premenopausal women with early-stage, ER+ breast cancer. The findings from these two studies were recently combined with findings from two other major trials in a major meta-analysis.

Results



Two presentations at SABCS addressed this work. The first reported on a meta-analysis of four randomized trials. The second updated findings from SOFT and TEXT, two of the four trials. The results were consistent.



The meta-analysis included 7,030 women in the ABCSG 12, TEXT, SOFT, and HOBOE trials. These trials started between 1999 and 2004. The median followup across trials was eight years. Some participants were treated with chemotherapy prior to or concurrently with the trial.



The trial randomized participant data into two groups – those who received AI and OFS and those who received tamoxifen and OFS. The study looked at recurrence and death.



They found that recurrence was more common in the tamoxifen group than the AI group. AI reduced the overall risk of recurrence by 21 percent and the risk of distant recurrence by 17 percent. Most of the benefit was seen in years two to four. There were no increases in deaths.



Subgroup analysis did not show differences by age, BMI, tumor size, tumor grade, or experience with chemotherapy. There was, however, a difference among node groups. Women with four or more nodes (N4+ disease) did not benefit from AI. In the subgroups with no nodes (N0) or fewer nodes (N1-3), AI worked well, improving over time even more than expected.



In terms of side effects, women who received AI experienced more bone fractures than those who took tamoxifen (5 percent compared to 3.8 percent).



The second presentation was an update on the TEXT and SOFT trials. The SOFT trial established the value of OFS plus tamoxifen. Both trials supported the meta-analysis finding that AI plus OFS did better at preventing recurrence than tamoxifen plus OFS. These women have already been followed for 12 to 13 years. Researchers continue to follow them to learn more about the impact of these medicines over time.

What it means for young women with early-stage disease



Premenopausal women with early-stage ER+ breast cancer with OFS now have an even better option for preventing recurrence. AI proved significantly more effective at keeping cancer from coming back than tamoxifen, which is highly effective as well. Tamoxifen continues to be recommended for premenopausal women with very low-risk, early-stage ER+ disease.



These studies did not show any differences in mortality. Researchers will continue to follow participants.



The side effects of the medicines are similar, but AI is more likely to cause bone fractures. The impact of this on quality of life needs to be factored into treatment decisions. Women choosing AI may want to take steps to improve or protect bone density.



AI was not effective for women with four or more cancerous nodes. This finding was unexpected. Based on prior research, the research team anticipated a strong response among women with high-risk disease. They do not have an explanation for this.
related_resources_article_carousel

Related resources

Tamoxifen

08/05/23 | BY: Reshma L. Mahtani

Tamoxifen is a type of hormonal therapy called a SERM, or selective estrogen receptor modulator, a medicine that prevents estrogen signals from getting to breast cancer cells.

Read More
 | 11 Min. Read |

Types of hormonal therapy

05/23/23 | BY: Jennifer Winn

Hormonal therapy medicines are in classes based on how they interact with the body’s natural hormones estrogen & progesterone. Some stop the body from making estrogen; others prevent estrogen from helping the cancer cell grow

Read More
 | 6 Min. Read |

Elacestrant

02/08/23 | BY: Virginia Kaklamani

Elacestrant (Orserdu) is a hormonal therapy used to treat metastatic breast cancer.

Read More
 | 5 Min. Read |

Treatments

06/30/22 | BY: LBBC Staff

Surgery, radiation, chemotherapy, hormonal therapy, targeted therapy, immunotherapy, breast reconstruction. Today, breast cancer treatment is more complicated than ever. We're here to help.

Read More
 | 3 Min. Read |

Ovarian suppression

11/05/19

Ovarian suppression is surgery, radiation therapy or medicine that is used in premenopausal women to stop the ovaries from working.

Read More
 | 4 Min. Read

Gonadotropin releasing hormone (GnRH) agonists

10/07/19 | BY: H. Irene Su

The gonadotropin releasing hormone agonists, or GnRH agonists, are a class of injectable medicines offered to pre- and perimenopausal women with breast cancer in order to temporarily suppress, or slow, ovarian function.

Read More
 | 5 Min. Read

What is hormonal therapy?

05/04/18 | BY: Katharine Campbell, Betsy Clark, Betty Harris, M. Tish Knobf, Ann H. Partridge, Edith Perez, Jennifer Winn

Hormonal therapy for breast cancer interferes with the signals that hormone receptors send to cells and may block estrogen receptors, reduce the amount of estrogen made, or lessen the number of hormone receptors.

Read More
 | 7 Min. Read |

Hormonal therapy

05/04/18 | BY: Jennifer Winn, M. Tish Knobf, Ann H. Partridge, Edith Perez, Betty Harris, Katharine Campbell, Betsy Clark

Hormonal therapy is using medicine or surgery to reduce estrogen in the body for cancers that depend on estrogen or progesterone to grow.

Read More
 | 3 Min. Read |

Fulvestrant

01/26/18 | BY: Jennifer Winn

Fulvestrant (Faslodex) is an estrogen receptor antagonist, or ERA, a class of medicine that stops the activity of estrogen on cancer cells to keep them from growing.

Read More
 | 4 Min. Read

Megestrol acetate

08/31/15 | BY: Jennifer Winn

Megestrol acetate is a progestin hormonal therapy. Progestins are human-made medicines that act like the natural hormone progesterone.

Read More
 | 4 Min. Read |
about_this_page_tabbed_module
About this page
Glossary
About LBBC

Jamie Kudera

Placeholder silhouette
  • Has been a contributor to LBBC since 2021
  • Reports on major scientific meetings and works to ensure LBBC's web content is current

Tagged:

Was this page helpful?

Living Beyond Breast Cancer is a national nonprofit organization that seeks to create a world that understands there is more than one way to have breast cancer. To fulfill its mission of providing trusted information and a community of support to those impacted by the disease, Living Beyond Breast Cancer offers on-demand emotional, practical, and evidence-based content. For over 30 years, the organization has remained committed to creating a culture of acceptance — where sharing the diversity of the lived experience of breast cancer fosters self-advocacy and hope. For more information, learn more about our programs and services.